Doozy Robotics Takes Physical AI Solutions Global with New Funding

Singapore’s Doozy Robotics has announced global expansion backed by seed funding, targeting the U.S., GCC, and Asia with humanoid industrial AI systems.

Singapore-based startup Doozy Robotics has announced a coordinated global expansion into the United States, the Gulf Cooperation Council (GCC) region, and Asia. The move is backed by seed-stage investors and marks a major step forward for the company as it prepares for a planned Series A funding round.

Backed by venture firm Cocoon Capital, the startup is building what it calls a vertically integrated physical AI ecosystem one designed to replace human labor in industrial environments at scale.

Founded by Suresh Chandrasekar and Ajmal Thahseen, Doozy Robotics develops autonomous industrial workforces. Rather than selling individual machines, the company offers an integrated platform. That platform combines three core systems: an Industrial Super Humanoid, a fleet of Autonomous Mobile Robots (AMRs), and Autonomous Forklifts.

Importantly, all three systems operate under a single proprietary intelligence layer called Eywa-OS. Designed to function as a super-intelligent factory manager, Eywa-OS interprets high-level production goals, allocates robots dynamically across the factory floor, and adapts to disruptions in real time.

Doozy is extending a Robot-as-a-Service (RaaS) model to cover its full multi-agent ecosystem. Instead of requiring customers to purchase hardware outright, the company offers a monthly subscription to an integrated autonomous workforce. Customers can scale humanoids and robots up or down as production demand shifts.

ALSO READ : AI Startup Hark Valued at $6B After New $700M Funding

Despite being at the seed stage, Doozy has already built a notable commercial track record. The company reports a qualified global pipeline worth more than $200 million. Additionally, it has signed a memorandum of understanding (MOU) valued at approximately $144 million with a major industrial conglomerate, which it has not yet named publicly.

Furthermore, Doozy is conducting a large-scale pilot of humanoid deployments with a U.S. pharmaceutical company. Paying customers are already live across two continents. Those customers include Daimler, Carrier, and VitaQuest.

We have been incredibly impressed by the sheer velocity of Doozy Robotics’ traction to date. Already having global customers actively deploying these systems across their warehouses and factories is a testament to the team’s execution.
Michael Blakey, Managing Partner at Cocoon Capital

The company’s expansion comes at a time when labor shortages are becoming a long-term structural problem not a temporary dip. In the United States alone, labor constraints are projected to contribute more than $1 trillion in negative GDP impact by 2030. Nearly half of American workers are over 45, and Gen Z represents just 8 percent of the current workforce.

The global labor shortage is a structural shift, not a temporary imbalance. We are building the Physical AI workforce that will power the next era of manufacturing. By combining humanoids, autonomous systems, and Eywa-OS orchestration, we are enabling facilities to operate with intelligence at scale. This expansion into the U.S. marks a critical step toward that vision.
Suresh Chandrasekar, CEO and Co-founder of Doozy Robotics

With its seed-stage milestones now in place, Doozy is actively preparing for a Series A fundraising round. The company has not disclosed the size of its seed round publicly.

The expansion into three major global markets simultaneously signals an aggressive growth strategy. Moreover, it reflects growing investor and enterprise confidence in physical AI as a viable, near-term solution to manufacturing labor challenges.

Disclaimer: This news is based on publicly available information. NervNow has not independently verified any claims.

DISCOVER LATEST AI INDUSTRY UPDATES
RSK Rolls Out Vaultiscan AI Platform for Companies
AI Startup Sprouts.ai Gets $9M in New Funding
AlphaGrep Uses AI to Make Mutual Fund Investing Simple
Harbour BioMed’s AI Drug LET003 Shows Strong Obesity Preclinical Results